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1. Introduction
Chronic bronchitis is more common in the elderly; it
refers to the chronic, non-specific inflammation of trachea,
surrounding tissue and bronchial mucosal inflammation.
Early symptoms of the disease are mild, the gradual
development of disease can lead to increased inflammation,
the symptoms can last for many years and develop into
pulmonary heart disease, emphysema and other diseases.
The pathology is characterized by hyperplasic of bronchial
glands and increase of mucus secretion,
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clinical manifestations is long-term expectoration, 
chronic cough, wheezing, etc. It is recurrent. Patients has 
significantly enlarged lungs breathe sounds, accompanied 
by wet and dry rales, increased white blood cells and 
X-ray texture. Chronic bronchitis is a common disease
of respiratory system. Patients have coughing, sputum
and other symptoms caused by mucosal inflammation or
excessive mucus secretion at bronchus. The sputum usually
appears white foam, because the attack is frequent, there
will be the symptoms of declined pulmonary function
and gradually declined respiratory function. Under the
premise of changed pathology, exposing to poison gas,
or season change, catching cold, overwork, smoking and
other factors may lead to a more acute disease tendency.
In the acute phase, corresponding signs or symptoms will
develop further on the basis of original pathology, at this
time, a large number of neutral granular cells infiltrations
lead to coughs more serious, severe congestion or edema
at the bronchus wall. While the glandular secretion
is more active, showing purulent sputum or purulent
characteristics. The condition becomes worse, this clinical
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ABSTRACT Objective: To discuss the effect of ambroxol hydrochloride 
injection on acute exacerbation of chronic bronchitis. Method: 83 cases of 
patients with acute exacerbation of chronic bronchitis were randomly divided 
into observation group and control group, both were given conventional 
treatment, observation group added ambroxol hydrochloride injection, the 
control group added bromhexine hydrochloride injection, the effect, PaO2 index 
and adverse reactions were compared. Result: The total effective rate (95.24%) 
and PaO2 index (71.22 ± 8.92) mmHg in the observation group were higher 
than those in the control group, and the occurrence of adverse reactions (4.76%) 
was lower than that of the control group, p  < 0.05. Conclusion: Ambroxol 
hydrochloride injection can effectively relieve acute exacerbation of chronic 
bronchitis, improve PaO2 index, and have fewer adverse reactions, be worthy of 
promotion.
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symptoms is urgently needed to alleviate and control. 
Therefore, on the basis of conventional asthma spasm and 
antibiotics therapy, cough suppressant & expectorant has a 
far-reaching significance for ensuring airway clear [1].
   Ambroxol hydrochloride injection has the characteristics 
of secretions decomposition and mucus exclusion, can 
effectively remove secretions and reduce mucous retention 
as much as possible, and improve patient respiratory 
conditions. Ambroxol hydrochloride injection can make 
patients return to normal mucus secretion, significantly 
reduce cough and sputum volume. Under the condition of 
not being hindered, the active substance in the respiratory 
mucosa can effectively play a normal protection function. 
At the same time, ambroxol hydrochloride injection has 
a similar effect of strengthening antibiotic concentration 
in lung tissue and the corresponding secretions, which 
significantly shorten the time of treatment with antibiotics. 
Therefore, the application of ambroxol hydrochloride 
injection has big benefits in treatment of respiratory 
diseases. To explore the therapeutic effect of ambroxol 
hydrochloride injection on acute exacerbation of chronic 
bronchitis, two different methods were used to treat 
patients in our hospital, and the effect, PaO2 index and 
adverse reactions were compared. Now the report is as 
follows [2].
2. Material and Method
2.1. General Information
83 patients with hypertensive cerebral hemorrhage, who
were treated in our hospital from July 2013 to July 2014, were
selected as research subjects, and randomly divided into
observation group and control group. Observation group
contained 20 female patients and 22 male patients, the age
range was 40 to 85 years old, mean age was 70.26 ± 5.49 years
old, the course of chronic bronchitis was from 4 to 18 years,
the average course of disease was (10.11 + 1.58) years; The
course of acute attack of chronic bronchitis was 5 to 15 days,
the average duration of disease was (6.33 + 2.12) days; there
were 10 cases with respiratory failure, 15 cases with coronary
heart disease, and 17 cases with hypertension. The control
group contained 21 female patients and 20 male patients,
the age range was 41 to 86 years old, mean age was 71.32 ±
5.11 years old; the course of chronic bronchitis was from 5
to 19 years, the average course of disease was (11.12 ± 1.63)
years; The course of acute attack of chronic bronchitis was 4
to 15 days, the average duration of disease was (6.41 ± 1.85)
days, there were 12 cases with respiratory failure, 13 cases
with coronary heart disease, and 16 cases with hypertension.
Statistical analysis showed that there was no significant
difference between two groups in gender, age, duration of
disease and other general information (p > 0.05), therefore,
the two groups were comparable.
2.2. Treatment Method
The observation group was treated with conventional 
therapy,  such as expectorant,  oxygen inhalat ion, 
ant-infection etc, on this basis, 30 mg of ambroxol 
hydrochloride injection dissolved in 250 mL of 5% glucose 
injection was given, 2times a day, continuous intravenous 
infusion for 14 days. The control group was treated with 
bromhexine hydrochloride injection on the basis of routine 
therapy, 1 time a day, and 10 mg each time. The treatment 
effect, PaO2 index and adverse events of the two groups 
were observed and compared after 14 days [3].
2.3. Efficacy Judgment
Therapeutic efficacy should be made according to the 
clinical guiding principle of medicine for eliminating 
phlegm and stopping cough developed by the Ministry of 
health food and Drug Administration. 
(1) Marked effect: Cough and corresponding symptoms
in chest X-ray, pulmonary rales, wheezing and other 
symptoms completely disappear or almost disappear, the 
sputum is completely or almost excluded, PaO2 is within 
the normal range (75 to 100 mmHg). 
(2) Effective: Cough, wheezing and other symptoms has
been relieved, a little sputum is not discharged, PaO2 index 
was close to normal;
(3) Ineffective: The above indicators have no change or
even worse than before.
   The total efficiency = (cases of marked effect + cases of 
effective)/ the total of cases × 100%.
2.4. Statistical methods
The acquired data was analyzed by SPSS 18.0 statistical 
software statistically. Measurement data were expressed as 
mean ± standard deviation and analyzed by t  test; count 
data were analyzed by X2 test, p < 0.05 was considered as 
statistical significance.
3. Results
3.1. Comparison of treatment effect
After 14 days of treatment, the total effective rate of
the observation group was 95.24%, the control group
was 75.61%. The total effective rate of the observation
group was higher than that of the control group, and the
difference was statistically significant (p < 0.05). See Table 1.









42 28 (66.67) 12 (28.57) 2 (4.76) 40 (95.24)
Control group 41 20 (48.78) 11 (26.83) 10 (24.39) 31 (75.61)
Note: the difference of total effective rate between two groups was 
statistically significant, p < 0.05.
3.2. Comparison of PaO2 index
After 14 days of treatment, the PaO2 index of the observation 
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group was (76.23 ± 9.33) mmHg, and the control group was 
(71.22 ± 8.92) mmHg. The PaO2 index of the observation 
group was higher than that of the control group, and the 
difference was significant,  p < 0.05.
3.3. Comparison of adverse events
After 14 days of treatment, there were 10 cases of patients 
with adverse reactions, the observation group accounted 
for 2 cases (1 case of indigestion, 1 case of vomiting), 
and the adverse reaction rate was 4.76%. The control 
group accounted for 8 cases (3 cases of indigestion, 2 
cases of vomiting, and 3 cases of serum aminotransferase 
elevating), the adverse reaction rate was 19.51%. The 
occurrence of adverse reactions in the observation group 
was significantly lower than that in the control group, and 
the difference was significant, p < 0.05.
4. Discussion
C hronic  bronchit i s  c aus e  non-sp e c i f i c  chronic
inflammation of the bronchus, trachea and surrounding
tissues because of infection or non-infectious factors,
the, frequent episodes of inflammation cause atrophy
and even rupture of submucosal smooth muscle bundles,
the progression of disease may lead to the fibrous tissue
hypertrophy of the trachea, lumen collapse, stiffness and
other symptoms appear, finally the airway is blocked.
The main symptoms were frequent cough, expectoration
accompanied by wheezing. At the time of acute attack,
it will be accompanied by severe cough, a lot of sputum,
severe wheezing and yellow sputum, viscosity of sputum
is big and different to cough out. The narrowed, deformed
respiratory tract may be blocked by sputum. Bacteria thrive
in the airway, leading to persistent infections, respiratory
failure, heart failure and other complications, which bring
a life-threatening to the patients. In addition to control
of infection, the key lies in the reasonable and scientific
expectorant. Especially for those who are elderly and
infirm, expectorant shall be listed as the key of treatment.
Therefore, seeking the best expectorant drugs has a far-
reaching significance for treatment of such disease. Acute
attack of chronic bronchitis can produce a large amount of
mucus secretion in a short time, while these secretions can
promote the secondary infection, it is often accompanied
by fever and other inflammatory manifestations, and
ultimately induces respiratory failure, heart failure and
other serious complications [4]. At the same time, the
symptoms of systematic fever may also cause respiratory
system and circulatory system failure, which can threaten
the patient’s life. The clinical treatment of the disease
mainly was anti-infection, and takes into account
expectorant in the meanwhile, improving ventilation.
Ambroxol hydrochloride injection has the function of
eliminating phlegm and dissolving exudates, can effectively 
eliminate the respiratory tract mucus secretion and reduces 
phlegm retention. Ambroxol hydrochloride injection is 
a kind of effective mucus dissolving medicament; it is an 
ideal drug in treatment of cough, expectorant and the 
patients’ improvement. The drug reacts with tracheal 
secretion cells, resulting in more secretion, enhancing 
ciliary swing. The scavenging ability of mucus transport 
system is also enhanced. The acid mucopolysaccharide 
fiber in sputum is decomposed, so the sputum is well 
diluted and easy to discharge, eventually improving 
the respiratory conditions. Ambroxol hydrochloride 
injection was well tolerated, the toxicity index is low, so 
it can be used for a long time, which is suitable for weak 
expectoration and unnormal mucus secretion patients 
with acute exacerbation of chronic bronchitis [5]. Besides, 
Mucosolvan is a kind of absorbing protective agent, has 
the function of inflammation inhibition, antioxidant and 
airway smooth muscle relaxation, and it is safe in clinical 
application.
   In our hospital, the observation group received treatment 
of ambroxol hydrochloride injection, the results of this 
study showed that the total effective rate (95.24%) and 
PaO2 index (76.23 ± 9.33) mmHg in the observation 
group were higher than those in the control group, p  < 
0.05. In addition, the occurrence of adverse reactions in 
the observation group (4.76%) was lower than that in the 
control group, p  < 0.05. Thus, ambroxol hydrochloride 
injection can effectively alleviate the condition of patients 
with acute exacerbations of chronic bronchitis, has the 
advantages of fast effect and high security, be worthy of 
popularization and application.
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